Navigation Links
Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
Date:8/22/2007

ary enrollment process administered through patients' healthcare providers, enrollees will have the comfort that GAMMAGARD LIQUID and GAMMAGARD S/D is available to them even if they experience changes involving their providers or site of care. A third party vendor will manage the program, and Baxter will not have access to patient data.

Enrollment in this program will be voluntary and will not automatically preclude those patients not participating in the program from accessing GAMMAGARD LIQUID and GAMMAGARD S/D. Baxter will continue to work closely with patient organizations and key thought leaders from different clinical specialties that prescribe IGIV therapy to launch the program. Patients not enrolling in the voluntary GARDian program will still be eligible for other GAMMAGARD patient programs (e.g. GAMMAssist and the Low IgA/Brand Intolerance Program and product Portability programs).

"Baxter has a long, proud history of advancing the science of IGIV therapy and serving the patients who rely on our IGIV therapies," said Larry Guiheen, president, Baxter Biopharmaceuticals, North America. "Baxter is committed to providing continued access to their therapy of choice for our patients. The GARDian program represents our continued commitment to that goal."

Patients and physicians can sign up to receive more information about the GARDian program at http://www.immunedisease.com.

About GAMMAGARD LIQUID 10%

GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

About GAMMAGARD S/D

GAMMAGARD S/D is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but
'/>"/>

SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. Weather information companies launch data product
7. TeraMedica launches information manager
8. GE Healthcare launches hybrid electronic record
9. Cedara launches new version of DICOM toolkit
10. Merge launches Spanish version of imaging tool
11. Orbitec will use $25 million Air Force contract to make small launch vehicle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... OncLive® is pleased to ... Thomas Jefferson University has joined its Strategic Alliance ... Partnership program, the Sidney Kimmel Cancer Center at ... of the Center’s cutting-edge research programs, comprehensive approach ... other health care professionals from the Sidney Kimmel ...
(Date:10/19/2014)... 2014 The Latin American hardware encryption ... Latin America with analysis and forecast of revenue. This ... is expected to reach $2,366.8 million by 2018, at ... Browse through the TOC of the Latin American hardware ... in-depth analysis provided. It also provides a glimpse of ...
(Date:10/19/2014)... 19, 2014 The Asia-Pacific Bromine ... in Asia-Pacific with analysis and forecast of revenue. ... Pacific Bromine Market report, to get an idea ... a glimpse of the segmentation in the Asia-Pacific ... and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The report ... Market Share, Trade, Prices, Geography Trend and Forecast (2011 ... sales category, and geography and studies the major market ... North America, Europe, and Asia. , The global chocolate ... 2010.to $98.3 billion in 2016 at an estimated CAGR ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... - New findings from the pivotal TEMSO Phase III study presented ... - U.S. FDA Accepts New Drug Application for   ... (EURONEXT: SAN and NYSE: SNY ) and its subsidiary Genzyme ... ultiple S clerosis O ral (TEMSO) Phase III trial showing ...
... scientists at the University of California at Berkeley ... viruses called M13 phages to serve as structural ... of properties. By controlling the physical environment ... into hierarchically organized thin-film structures, with complexity that ...
... Fla., Oct. 19, 2011 Physicians and scientists ... just released the results of their groundbreaking research ... Impairs Embryonic Reproductive Potential While Blastocyst Biopsy Does ... and Non-Biopsied Sibling Embryos.   The study, led ...
Cached Biology Technology:Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 2Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 3Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 4Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 5Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 6Manufacturing goes viral 2Manufacturing goes viral 3Manufacturing goes viral 4Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 2Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 3
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
(Date:10/16/2014)... how the bowel lining develops and, in the process, ... , The researchers produced evidence that stem cells are ... a feature of the bowel lining, and believe these ... controversial finding as scientists are still divided on the ... Chin Wee Tan and Professor Tony Burgess from the ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... out at the University of Haifa has found that bees ... over nectar that does not comprise these substances at all. ... bee addicted, the researchers say.* Bees prefer nectar with ... not comprise these substances at all, a study from the ...
... School of Medicine,s (BUSM) Slone Epidemiology Center and Boston ... pre-pregnancy obesity and gestational weight gain are associated with ... participants from the Black Women,s Health Study. This study ... baby born at less than 37 weeks of gestation ...
... (February 10, 2010) New research from the Monell Center ... to both a family history of alcoholism and the child,s ... how liking for sweets differs among children based on underlying ... is rewarding to all kids and makes them feel good," ...
Cached Biology News:Are bees also addicted to caffeine and nicotine? 2Prepregnancy, obesity and gestational weight gain influence risk of preterm birth 2Intense sweets taste especially good to some kids 2
... plus,for Reliable Sterile Filtration of Tissue Culture ... pump or tube pump, quickly and,reliably sterilize ... aqueous solutions. The combination of a ... de-aeration,ensures high flow rates and optimal total,throughputs. ...
... The EasyCount System is a fluorescent microscopy-based ... live nucleated cells and automatically calculates cell ... automating this routine function, the variability associated ... can be eliminated. Using the EasyCount ViaSure ...
... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
... paper sandwiches are composed of a precut ... thick filter paper that are preassembled into ... These 7 x 8.5 cm membrane sandwiches ... Gel-sized gels and are supplied as a ...
Biology Products: